SEHK:1672Biotechs
Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?
Ascletis Pharma (SEHK:1672) has attracted investor attention after receiving U.S. FDA Investigational New Drug clearance for ASC35, a once-monthly dual GLP-1/GIP agonist that is being advanced into a Phase I obesity trial.
See our latest analysis for Ascletis Pharma.
The FDA IND clearance arrives after a volatile year for Ascletis Pharma, with the share price down 35.2% over the past month and 37.9% over three months, while still delivering a 3-year total shareholder return of 418.5% and a...